These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23746455)

  • 1. Utilizing poxviral vectored vaccines for antibody induction-progress and prospects.
    Draper SJ; Cottingham MG; Gilbert SC
    Vaccine; 2013 Sep; 31(39):4223-30. PubMed ID: 23746455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
    Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
    Front Immunol; 2019; 10():2941. PubMed ID: 31921191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
    Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
    Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
    Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate immune recognition of poxviral vaccine vectors.
    Lousberg EL; Diener KR; Brown MP; Hayball JD
    Expert Rev Vaccines; 2011 Oct; 10(10):1435-49. PubMed ID: 21988308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
    Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
    J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progresses in DNA-based heterologous prime-boost immunization strategies.
    Jackson RJ; Boyle DB; Ranasinghe C
    Methods Mol Biol; 2014; 1143():61-90. PubMed ID: 24715282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination.
    Zhong C; Liu F; Hajnik RJ; Yao L; Chen K; Wang M; Liang Y; Sun J; Soong L; Hou W; Hu H
    J Virol; 2021 Oct; 95(22):e0092521. PubMed ID: 34495698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates.
    Zhan Y; Deng Y; Huang B; Song Q; Wang W; Yang Y; Dai L; Wang W; Yan J; Gao GF; Tan W
    Vaccine; 2019 Apr; 37(15):2122-2130. PubMed ID: 30851967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.
    Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD
    Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
    Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
    Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.
    Karkhanis LU; Ross TM
    Curr Pharm Des; 2007; 13(19):2015-23. PubMed ID: 17627535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.
    de Cassan SC; Draper SJ
    Expert Rev Vaccines; 2013 Apr; 12(4):365-78. PubMed ID: 23560918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
    Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE
    Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant poxviruses as mucosal vaccine vectors.
    Gherardi MM; Esteban M
    J Gen Virol; 2005 Nov; 86(Pt 11):2925-2936. PubMed ID: 16227213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.